tough trough build global allergi
franchis trim pt
greater pressur legaci eu scit/slit-drop sale evid drive
wider loss margin pressur intensifi invest slit-tablet
 infrastructur believ aim manag growth strategi
achiev least organ growth ebit margin
assum howev absent rapid us adopt odactra hous
dust mite tab expect share remain rang bound henc hold
pain necessari transform signific invest requir set
sustain futur growth trajectori upgrad capac manufactur system
plu rolling-out us ramping-up complet slit-tablet portfolio
believ organ sale compound-annual-growth-rate achiev beyond forecast
ebit margin broadli in-lin wider specialti pharma
target rang outflow like near outlook exceed
cash suggest need bridg financ assum nomin dividend
pay-out resum
us may slow tough assum target specialist captur nich
segment estim peak sale substanti estim run-
rate prior partner merck given shot highli profit busi focu
drive adopt patient refus therapi daili slit-tablet potenti
prefer see remain challeng commerci backdrop benefit
also odactra hous dust mite hdm slit-tablet top grastek grass
ragwitek ragwe unlik europ allerg asthma hdm label claim
note fda endors design paediatr phase asthma allergi studi
could provid pathway label indic
wider loss lower scit/slit-drop cut eu legaci sale given weaker
on-going suppli disrupt drive price
share slightli optimist manag aim larg driven perhap
greater adopt acarizax/odactra hdm tablet
price base npv sum-of-the-part valuat risk
includ clinic regulatori setback sluggish adopt slit-tablet
us competitor newsflow pressur eu base busi
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
oper leverag plu benefit effici
programm underpin confid european base
busi gener npv around dkk
optimist ramp-up acarizax hous dust mite
slit-tablet market ex-us/japan given benefit
allerg asthma label claim
must commercialis slit-tablet
us merck return right increas execut risk
dkk per share price base npv sum-of-
dilut fund cash shortfal
higher hdm slit-tablet peak penetr market
ex-us/japan patient base case could
boost npv around dkk
greater adopt slit-tablet us
patient peak base case could boost
npv around dkk
togeth event plu potenti upsid
conserv forecast japan could boost npv
deriv price around dkk
lower hdm slit-tablet peak penetr market
ex-us/japan patient could lower npv
sluggish ramp-up slit-tablet us
patient peak could potenti lower npv
eu regulatori delay reject birch tree slit-
potenti risk plu on-going headwind
eu sale could lower npv deriv price
around dkk
work allergi field number
year lead share global allergi
vaccin market expert product
allergen allergi vaccin complex process
repres signific barrier entri view
ensur long product lifecycl without gener
us launch slit-tablet updat
manag progress
birch tree slit-tablet eu regulatori file
quarterli result demonstr robust trend core
eu allergi franchis oper leverag effici
programm implement
page
pleas see import disclosur inform page report
retain hold pt dkk
still envisag rel steadi growth grazax allergi
immunotherapi tablet slit-tablet europ first diseas modifi
tablet hayfev optimist ramp-up acarizax
slit-tablet hous dust mite benefit label claim allerg
asthma patient long-term oper leverag ramp-up
higher margin tablet drive earn momentum royalti
incom partner torii japan collabor asia could also
acceler growth howev cautiou commerci potenti
slit-tablet potenti lucr us allergi market may
slow challeng task acceler us uptak target
 strategi given allergologist focu administ shot price
cut dkk dkk per share base npv sum-
larg reflect higher near-term spend
implement growth strategi outlin manag
set transit year expect
manag envisag revenu cer yoy robust
growth slit-tablet off-set expect price reduct tighter reimburs
southern europ notabl franc suppli constraint upgrad legaci
busi signific product rationalis combin advers effect
top-lin still foreseen dkk pressur southern europ
reiter four key aim within growth strategi
invest north america plan invest dkk maximis
commerci opportun estim allergi suffer
us elig receiv immunotherapi one-third actual
shot quadrupl north american field forc around
staff focus initi high frequenc interact
relev allergi specialist long-term target prescrib base
expand reach addit financi model still assum
 dkk spend us
invest complet slit-tablet portfolio manag
envisag spend rang dkk per annum next
five year clinic studi two paediatr hdm trial allerg
asthma rhiniti involv total subject europ north
america studi tree slit-tablet children us paediatr safeti
trial ragwitek addit on-going paediatr efficaci studi
on-going us post-market surveil studi remain in-lin
forecast
develop system engag patient new consum divis
establish engag patient primarili via internet market
research suggest allergi suffer rare see doctor trend
toward self-med new rang support tool launch
intervent guidanc symptom alleviation/relief
medic adher tool manag also evalu relat commerci
opportun respiratori drug anaphylact partnership in-
licens deal acquisit consider cost execut
potenti transact possibl revenu gain includ
strateg goal assum in-licens deal within
forecast
optimis realloc resourc primari focu simplifi product
suppli improv gross margin rationalis scit slit-
drop portfolio upgrad manufactur system streamlin
page
pleas see import disclosur inform page report
organis assum gross margin return prior level
reflect invest capac cost
tabl long-term forecast broadli similar manag aim
tabl slash profit lower scit/slit-drop revenu updat fx headwind
tabl estim manag initi target
us execut may slow challeng
sale forecast us slit-tablet probabl
commerci success perhap conserv peak sale
news flow us launch trend regular prescript data quarterli
updat manag
initi us adopt slit-tabl much sluggish hope despit
market effort big pharma compani merck hold merck receiv us
fda approv grastek market grazax europ april ragwitek
three day later april late launch ahead allergi season
nevertheless season estim in-market us sale
per annum juli merck announc follow recent
review strateg prioriti partnership agreement would end
right slit-tablet north american revert januari odactra
page
pleas see import disclosur inform page report
growth revenu growth beyond margin in-lin wider specialti cash flow million dec chgoldnew chgoldnew chgtotal gross margin market admin oper margin net ep revenu base revenueslightli adjust alkb dc
hous dust mite fda approv march prolong period
bla dossier three slit-tablet transfer august
clear way us re-launch focus commerci strategi
estim around patient inject allergi immunotherapi shot
us perhap off-label slit-drop addit could potenti
around patient either tri shot perhap due needle-phobia
discontinu treatment shot howev despit signific pool potenti
patient slit-tablet believ primari hurdl merck face like reluct
allergologist prescrib product given highli profit busi
formul administ shot
assum challeng commerci backdrop addit pharma compani
still activ promot allergi drug like make difficult acceler
adopt slit-tablet long-term fda approv label odactra
incorpor benefit reduc exacerb allerg asthma patient case
current europ believ may feasibl drive growth focus
pulmonologist potenti requir assist us partner recent made
import step achiev goal fda agre phase design
acarizax/odactra paediatr sever asthma allerg patient aim event
driven studi demonstr hdm slit-tablet reduc risk sever asthma
exacerb expect trial commenc shortli result
forecast us peak sale assum patient receiv slit-tablet
captur share three slit-tablet price per
tablet discount rebat coupon like result total gross-to-net
deduct view odactra commerci valuabl slit-
tablet dust mite perenni allergen rather season product
compel clinic data allerg asthma patient
acarizax gain traction europ
sale forecast slit-tablet europ ex-us/japan
market risk adjust
news flow increment launch acarizax price
reimburs secur eu regulatori file tree slit-tablet
sale slit-tablet like driven acarizax hous dust mite hdm
rolled-out across new market forecast peak sale slit-
tablet market ex-us/japan six time current run-rat
growth underpin improv reimburs secur
clinic data wider access awar physician patient regul
encourag switch named-pati product therapi formal approv
perhap importantli launch new geographi includ sale
birch pollen ragwe pollen slit-tablet ex-us/japan
acarizax first slit-tablet approv hdm allerg rhiniti allerg
asthma approv european countri regulatori approv also
recent grant spain ensur success commerci launch prioriti
initi focu allergi commun order gain accept
advocaci ultim incorpor medic guidelin product choic
importantli februari revis gina guidelin asthma incorpor use
slit-tablet long-term effort like expand includ respiratori
specialist leverag label claim allerg asthma
page
pleas see import disclosur inform page report
